Cognome - Nome |
TESTI Roberto |
Posizione |
Professore Ordinario |
Telefono |
+39 06 7259 6503 |
S.S.D. |
MED/04 |
S.C. |
06/A2 |
e-mail |
|
Interessi di Ricerca |
Struttura e funzione di recettori di membrana linfocitari. Trasmissione del segnale recettoriale nella attivazione e morte cellulare dei linfociti. Attivazione delle cellule dendritiche. Sviluppo di strategie terapeutiche per la atassia di Friedreich. |
FORMAZIONE
1982 Laurea in Medicina e Chirurgia, Universita’ di Roma “La Sapienza”
Principali esperienze accademiche e professionali
1986 - 1987 Postdoc, Dana Farber Cance Center, Harvard University, Boston (MA), USA
1987 - 1989 Postdoc, Becton Dickinson Monoclonal Center, Mountain View (CA), USA
1988 - 1990 Research Associate, University of California, San Francisco (CA), USA
1988 - 1992 Ricercatore universitario, Patologia Generale, Universita’ di L’Aquila
1992 - 2000 Professore Associato, Patologia Generale, Universita’ di Roma “Tor Vergata”
1994 - date Direttore del Laboratory of Signal Transduction (www.labst.org), Universita’ di Roma “Tor Vergata”. Il LABST e’ stato finanziato da European Commission (IV, V, VI Framework Programs, European Research Council), Telethon, Associazione Italiana Ricerca sul Cancro, Ministero della Sanita’, Ministero della Ricerca, Consiglio Nazionale delle Ricerche, Friedreich Ataxia Research Alliance, Ataxia UK, National Ataxia Foundation, Ataxia Ireland, Association Francaise de l’Ataxie de Friedreich
1999 - 2005 Coordinatore del Dottorato di Ricerca in “Fisiopatologia della morte cellulare”
2000 - pres Professore Ordinario, Immunologia, Universita’ di Roma “Tor Vergata”
2011 ERC Advanced Grant awardee “Friedreich Ataxia Seeks Therapy - FAST”
2015 ERC Proof-of-Concept Grant awardee “FAST develops”
2015 - 2022 Fondatore e Presidente di Fratagene Therapeutics srl, startup finalizzata allo sviluppo di una terapia per la atassia di Friedreich. Brevetti concessi: Testi R, Incani O. Compositions and methods for treating Friedreich's ataxia, US patent 8,703,749 (2014). Testi R. Tomassini B. Methods for treating Friedreich's ataxia with interferon gamma, US patent 8,815,230 (2014), European patent 2,611,457 (2014), entrambi licenziati (2016). Testi R. Frataxin mutants, US patent 9,217,019 (2015), European patent 2,598,525 (2015), European patent 9,944,906 (2018). Testi R, Incani O, Rufini A, De Martino G. Compositions and methods for treating Friedreich's ataxia, US patent 10,442,779 (2019). Rufini A, Alfedi G, Testi R. Methods for treating Friedreich's ataxia with etravirine, US patent 10,426,775 (2019).
Principali pubblicazioni
Franchi L, Condò I, Tomassini B, Nicolò C, Testi R. A caspaselike activity is triggered by LPS and is required for survival of human dendritic cells. Blood. 2003 Oct 15;102(8):2910-5.
Malisan F, Franchi L, Tomassini B, Ventura N, Condò I, Rippo MR, Rufini A, Liberati L, Nachtigall C, Kniep B, Testi R. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J Exp Med. 2002 Dec 16;196(12):1535-41.
De Maria R, Rippo MR, Schuchman EH, Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J Exp Med. 1998 Mar 16;187(6):897-902.
Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998 Oct 1;92(7):2244-51.
Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997 Feb 14;275(5302):960-3.
De Maria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, Rippo MR, Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science. 1997 Sep 12;277(5332):1652-5.
Sallusto F, Nicolò C, De Maria R, Corinti S, Testi R. Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med. 1996 Dec 1;184(6):2411-6.
Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med. 1994 Oct 1;180(4):1547-52.
Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A. CD69 is expressed on platelets and mediates platelet activation and aggregation. J Exp Med. 1990 Sep 1;172(3):701-7.
Lanier LL, Cwirla S, Yu G, Testi R, Phillips JH. Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. Science. 1989 Dec 22;246(4937):1611-3.
1982 Laurea in Medicina e Chirurgia, Universita’ di Roma “La Sapienza”
Principali esperienze accademiche e professionali
1986 - 1987 Postdoc, Dana Farber Cance Center, Harvard University, Boston (MA), USA
1987 - 1989 Postdoc, Becton Dickinson Monoclonal Center, Mountain View (CA), USA
1988 - 1990 Research Associate, University of California, San Francisco (CA), USA
1988 - 1992 Ricercatore universitario, Patologia Generale, Universita’ di L’Aquila
1992 - 2000 Professore Associato, Patologia Generale, Universita’ di Roma “Tor Vergata”
1994 - date Direttore del Laboratory of Signal Transduction (www.labst.org), Universita’ di Roma “Tor Vergata”. Il LABST e’ stato finanziato da European Commission (IV, V, VI Framework Programs, European Research Council), Telethon, Associazione Italiana Ricerca sul Cancro, Ministero della Sanita’, Ministero della Ricerca, Consiglio Nazionale delle Ricerche, Friedreich Ataxia Research Alliance, Ataxia UK, National Ataxia Foundation, Ataxia Ireland, Association Francaise de l’Ataxie de Friedreich
1999 - 2005 Coordinatore del Dottorato di Ricerca in “Fisiopatologia della morte cellulare”
2000 - pres Professore Ordinario, Immunologia, Universita’ di Roma “Tor Vergata”
2011 ERC Advanced Grant awardee “Friedreich Ataxia Seeks Therapy - FAST”
2015 ERC Proof-of-Concept Grant awardee “FAST develops”
2015 - 2022 Fondatore e Presidente di Fratagene Therapeutics srl, startup finalizzata allo sviluppo di una terapia per la atassia di Friedreich. Brevetti concessi: Testi R, Incani O. Compositions and methods for treating Friedreich's ataxia, US patent 8,703,749 (2014). Testi R. Tomassini B. Methods for treating Friedreich's ataxia with interferon gamma, US patent 8,815,230 (2014), European patent 2,611,457 (2014), entrambi licenziati (2016). Testi R. Frataxin mutants, US patent 9,217,019 (2015), European patent 2,598,525 (2015), European patent 9,944,906 (2018). Testi R, Incani O, Rufini A, De Martino G. Compositions and methods for treating Friedreich's ataxia, US patent 10,442,779 (2019). Rufini A, Alfedi G, Testi R. Methods for treating Friedreich's ataxia with etravirine, US patent 10,426,775 (2019).
Principali pubblicazioni
Franchi L, Condò I, Tomassini B, Nicolò C, Testi R. A caspaselike activity is triggered by LPS and is required for survival of human dendritic cells. Blood. 2003 Oct 15;102(8):2910-5.
Malisan F, Franchi L, Tomassini B, Ventura N, Condò I, Rippo MR, Rufini A, Liberati L, Nachtigall C, Kniep B, Testi R. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J Exp Med. 2002 Dec 16;196(12):1535-41.
De Maria R, Rippo MR, Schuchman EH, Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J Exp Med. 1998 Mar 16;187(6):897-902.
Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998 Oct 1;92(7):2244-51.
Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997 Feb 14;275(5302):960-3.
De Maria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, Rippo MR, Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science. 1997 Sep 12;277(5332):1652-5.
Sallusto F, Nicolò C, De Maria R, Corinti S, Testi R. Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med. 1996 Dec 1;184(6):2411-6.
Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med. 1994 Oct 1;180(4):1547-52.
Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A. CD69 is expressed on platelets and mediates platelet activation and aggregation. J Exp Med. 1990 Sep 1;172(3):701-7.
Lanier LL, Cwirla S, Yu G, Testi R, Phillips JH. Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. Science. 1989 Dec 22;246(4937):1611-3.
Family Name- Name |
TESTI Roberto |
Position |
Full Professor |
Telefono |
+39 06 7259 6503 |
S.S.D. |
MED/04 |
S.C. |
06/A2 |
e-mail |
EDUCATION
1982 M.D. Degree, University of Rome “La Sapienza”
Main academic and professional experience
1986 - 1987 Postdoc, Dana Farber Cance Center, Harvard University, Boston (MA), USA
1987 - 1989 Postdoc, Becton Dickinson Monoclonal Center, Mountain View (CA), USA
1988 - 1990 Research Associate, University of California, San Francisco (CA), USA
1988 - 1992 Researcher, Pathology, University of L’Aquila
1992 - 2000 Associate Professor, Pathology, University of Rome “Tor Vergata”
1994 - date Director of the Laboratory of Signal Transduction (www.labst.org), University of Rome “Tor Vergata”. The LABST has been funded by the European Commission (IV, V, VI Framework Programs, European Research Council), Telethon, Associazione Italiana Ricerca sul Cancro, Ministero della Sanita’, Ministero della Ricerca, Consiglio Nazionale delle Ricerche, Friedreich Ataxia Research Alliance, Ataxia UK, National Ataxia Foundation, Ataxia Ireland, Association Francaise de l’Ataxie de Friedreich
1999 - 2005 Director of the PhD Program in “Physiopathology of programmed cell death”
2000 - date Full Professor, Immunology, University of Rome “Tor Vergata”
2011 ERC Advanced Grant awardee “Friedreich Ataxia Seeks Therapy - FAST”
2015 ERC Proof-of-Concept Grant awardee “FAST develops”
2015 - 2022 Founder and President of Fratagene Therapeutics srl, startup company aimed at the development of a therapy for Friedreich ataxia. Granted patents: Testi R, Incani O. Compositions and methods for treating Friedreich's ataxia, US patent 8,703,749 (2014). Testi R. Tomassini B. Methods for treating Friedreich's ataxia with interferon gamma, US patent 8,815,230 (2014), European patent 2,611,457 (2014), both licensed (2016). Testi R. Frataxin mutants, US patent 9,217,019 (2015), European patent 2,598,525 (2015), European patent 9,944,906 (2018). Testi R, Incani O, Rufini A, De Martino G. Compositions and methods for treating Friedreich's ataxia, US patent 10,442,779 (2019). Rufini A, Alfedi G, Testi R. Methods for treating Friedreich's ataxia with etravirine, US patent 10,426,775 (2019).
Selected publications
Franchi L, Condò I, Tomassini B, Nicolò C, Testi R. A caspaselike activity is triggered by LPS and is required for survival of human dendritic cells. Blood. 2003 Oct 15;102(8):2910-5.
Malisan F, Franchi L, Tomassini B, Ventura N, Condò I, Rippo MR, Rufini A, Liberati L, Nachtigall C, Kniep B, Testi R. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J Exp Med. 2002 Dec 16;196(12):1535-41.
De Maria R, Rippo MR, Schuchman EH, Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J Exp Med. 1998 Mar 16;187(6):897-902.
Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998 Oct 1;92(7):2244-51.
Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997 Feb 14;275(5302):960-3.
De Maria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, Rippo MR, Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science. 1997 Sep 12;277(5332):1652-5.
Sallusto F, Nicolò C, De Maria R, Corinti S, Testi R. Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med. 1996 Dec 1;184(6):2411-6.
Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med. 1994 Oct 1;180(4):1547-52.
Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A. CD69 is expressed on platelets and mediates platelet activation and aggregation. J Exp Med. 1990 Sep 1;172(3):701-7.
Lanier LL, Cwirla S, Yu G, Testi R, Phillips JH. Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. Science. 1989 Dec 22;246(4937):1611-3.
1982 M.D. Degree, University of Rome “La Sapienza”
Main academic and professional experience
1986 - 1987 Postdoc, Dana Farber Cance Center, Harvard University, Boston (MA), USA
1987 - 1989 Postdoc, Becton Dickinson Monoclonal Center, Mountain View (CA), USA
1988 - 1990 Research Associate, University of California, San Francisco (CA), USA
1988 - 1992 Researcher, Pathology, University of L’Aquila
1992 - 2000 Associate Professor, Pathology, University of Rome “Tor Vergata”
1994 - date Director of the Laboratory of Signal Transduction (www.labst.org), University of Rome “Tor Vergata”. The LABST has been funded by the European Commission (IV, V, VI Framework Programs, European Research Council), Telethon, Associazione Italiana Ricerca sul Cancro, Ministero della Sanita’, Ministero della Ricerca, Consiglio Nazionale delle Ricerche, Friedreich Ataxia Research Alliance, Ataxia UK, National Ataxia Foundation, Ataxia Ireland, Association Francaise de l’Ataxie de Friedreich
1999 - 2005 Director of the PhD Program in “Physiopathology of programmed cell death”
2000 - date Full Professor, Immunology, University of Rome “Tor Vergata”
2011 ERC Advanced Grant awardee “Friedreich Ataxia Seeks Therapy - FAST”
2015 ERC Proof-of-Concept Grant awardee “FAST develops”
2015 - 2022 Founder and President of Fratagene Therapeutics srl, startup company aimed at the development of a therapy for Friedreich ataxia. Granted patents: Testi R, Incani O. Compositions and methods for treating Friedreich's ataxia, US patent 8,703,749 (2014). Testi R. Tomassini B. Methods for treating Friedreich's ataxia with interferon gamma, US patent 8,815,230 (2014), European patent 2,611,457 (2014), both licensed (2016). Testi R. Frataxin mutants, US patent 9,217,019 (2015), European patent 2,598,525 (2015), European patent 9,944,906 (2018). Testi R, Incani O, Rufini A, De Martino G. Compositions and methods for treating Friedreich's ataxia, US patent 10,442,779 (2019). Rufini A, Alfedi G, Testi R. Methods for treating Friedreich's ataxia with etravirine, US patent 10,426,775 (2019).
Selected publications
Franchi L, Condò I, Tomassini B, Nicolò C, Testi R. A caspaselike activity is triggered by LPS and is required for survival of human dendritic cells. Blood. 2003 Oct 15;102(8):2910-5.
Malisan F, Franchi L, Tomassini B, Ventura N, Condò I, Rippo MR, Rufini A, Liberati L, Nachtigall C, Kniep B, Testi R. Acetylation suppresses the proapoptotic activity of GD3 ganglioside. J Exp Med. 2002 Dec 16;196(12):1535-41.
De Maria R, Rippo MR, Schuchman EH, Testi R. Acidic sphingomyelinase (ASM) is necessary for fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J Exp Med. 1998 Mar 16;187(6):897-902.
Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood. 1998 Oct 1;92(7):2244-51.
Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, Ruberti G, Bagnasco M, Testi R, Galluzzo A. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 1997 Feb 14;275(5302):960-3.
De Maria R, Lenti L, Malisan F, d'Agostino F, Tomassini B, Zeuner A, Rippo MR, Testi R. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science. 1997 Sep 12;277(5332):1652-5.
Sallusto F, Nicolò C, De Maria R, Corinti S, Testi R. Ceramide inhibits antigen uptake and presentation by dendritic cells. J Exp Med. 1996 Dec 1;184(6):2411-6.
Cifone MG, De Maria R, Roncaioli P, Rippo MR, Azuma M, Lanier LL, Santoni A, Testi R. Apoptotic signaling through CD95 (Fas/Apo-1) activates an acidic sphingomyelinase. J Exp Med. 1994 Oct 1;180(4):1547-52.
Testi R, Pulcinelli F, Frati L, Gazzaniga PP, Santoni A. CD69 is expressed on platelets and mediates platelet activation and aggregation. J Exp Med. 1990 Sep 1;172(3):701-7.
Lanier LL, Cwirla S, Yu G, Testi R, Phillips JH. Membrane anchoring of a human IgG Fc receptor (CD16) determined by a single amino acid. Science. 1989 Dec 22;246(4937):1611-3.
|
Dipartimento di Biomedicina e Prevenzione
Department Biomedicine and Prevention Facoltà di Medicine e Chirurgia Faculty of Medicine and Surgery Università di Roma Tor Vergata University of Rome Tor Vergata Indirizzo/Address: Viale Montpellier, 1 – Roma (Studio D12) |
Direttore del Dipartimento / Director of the Department Prof. Antonio De Lorenzo Responsabile Amministrativo / Administrative Head Avv. Ombretta Picchioni Content manager del sito / Content manager of the website Prof. Andrea Malizia |